VXRT - Vaxart Reports More Positive Data From Animal Testing of Its Coronavirus Vaccine Candidate
Vaxart (NASDAQ: VXRT) on Thursday reported new details from a pre-clinical animal study of the company's COVID-19 vaccine candidate. According to the company, there was "significant reduction" of lung viral load in hamsters that received the vaccine, compared to non-vaccinated animals. And there was evidence that it generated a strong immune system response, as the vaccinated animals displayed antibody titers above 10,000.
"These additional data provide further evidence supporting the efficacy potential of our oral COVID-19 vaccine candidate," said CEO Andrei Floroiu. "In addition, we believe that our room-temperature-stable oral tablet vaccine would be a more convenient, more practical solution to the COVID-19 pandemic as compared to cold-chain dependent injectable vaccines."
Image source: Getty Images
For further details see:
Vaxart Reports More Positive Data From Animal Testing of Its Coronavirus Vaccine Candidate